The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Aspirin and Extended-Release Dipyridamole
Aspirin and Extended-Release Dipyridamole · ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg/1 · Capsule · Oral · AvKARE
NDC 42291-0116-60 · 60 CAPSULE in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$60.00
Reported to Texas DSHS · 2026 annual filing · AvKare
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for aspirin and extended-release dipyridamole (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Opioid Analgesic REMS Shared System REMS
Regulatory
- Application
- ANDA206392
- TE code
- AB
- Approval date
- Mar 8, 2016
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Aspirin and Extended-Release Dipyridamole (Capsule)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Aspirin and Extended-Release Dipyridamole — NDC 42291-0116-60," retrieved September 3, 2026, https://drugdashboards.com/drug/42291011660.
Free to cite with attribution — see how the data is put together.